目的：诱骗受体3（decoy receptor 3，DcR3）是肿瘤坏死因子受体（TNFR）家族的成员，影响着多种肿瘤的发生发展，本实验研究探讨其与卵巢癌发生发展及预后的关系。方法：应用免疫组织化学SP法检测38例正常卵巢组织、29例卵巢良性肿瘤及86例卵巢上皮性癌组织中DcR3蛋白的表达情况。结果：DcR3蛋白在卵巢癌组织中的表达明显高于卵巢良性肿瘤及正常组织中的表达；DcR3蛋白在卵巢上皮性癌Ⅰ-Ⅱ期表达较Ⅲ-Ⅳ期明显减弱；在高中分化组织中的表达明显低于低分化组织；在淋巴结转移组的表达高于无淋巴结转移组，各组间差异均具有统计学意义（p<0.05）。DcR3蛋白表达越强，患者生存时间越短（p<0.05）。结论：DcR3表达水平与卵巢上皮性癌临床分期、组织分化、肿瘤浸润、转移及预后有关，有可能成为一种卵巢癌肿瘤特异性指标。%Objective:Decoy receptor 3(DcR3),a new member of tumor necrosis factor receptor(TNFR)super-family,is not only upregulated in cancer cells derived from various cell lineages,but also correlates with the overall survival of certain cancer patients. We studied a possible association between DcR3 expression and prognosis in pa-tients with epithelial ovarian carcinoma. Methods:Protein expression of DcR3 was compared in 38 normal human o-varian tissues,29 benign ovarian tissues and 86 epithelial ovarian cancer( EOC)by immunohistochemistry( IHC). Re-sults:Expression of DcR3 in EOC was significantly higher than that in normal ovarian tissues(p<0. 01)and benign ovarian tissues(p<0. 05),respectively. It was also found that DcR3 expression in well differentiated EOC was signifi-cantly low than that in poorly differentiated specimens(p<0. 05). Patients in stages I and II showed significantly low-er DcR3 expression compared with that in stages III and IV(p<0. 05). DcR3 expression in lymph node metastasis-negative patients was significantly decreased in comparison with that in lymph node metastasis-positive patients( p<0. 05). Conclusion:DcR3 protein expression is significantly over-expressed in malignant tumors compared to normal ovaries and benign tumors. While it is relatively unchanged in benign tumors compared to normal ovary. The DcR3 gene might serve as an important molecular biological indicator in diagnosing and predicating the clinical outcome in EOC patients.
展开▼
